[go: up one dir, main page]

PE20211489A1 - Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso - Google Patents

Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso

Info

Publication number
PE20211489A1
PE20211489A1 PE2021000260A PE2021000260A PE20211489A1 PE 20211489 A1 PE20211489 A1 PE 20211489A1 PE 2021000260 A PE2021000260 A PE 2021000260A PE 2021000260 A PE2021000260 A PE 2021000260A PE 20211489 A1 PE20211489 A1 PE 20211489A1
Authority
PE
Peru
Prior art keywords
vitamin
dosage forms
preparation
methods
pediatric dosage
Prior art date
Application number
PE2021000260A
Other languages
English (en)
Inventor
Praful Balavant Deshpande
Stephen James Quinlan
Marta Golec
John Gerard O'brien
James Joseph Mcdonald
Reem Elamein Elsiddig
Ken O'shea
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of PE20211489A1 publication Critical patent/PE20211489A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta referido a formas de dosificacion de compuestos de vitamina D de liberacion prolongada, que comprenden un compuesto de vitamina D, opcionalmente 25-hidroxivitamina D o calcifediol, disperso en una composicion polimerica. Tambien se refiere a formulaciones de vitamina D de liberacion prolongada, incluyendo formulaciones adecuadas para el suministro a pacientes pediatricos que necesitan del tratamiento. Tales formulaciones pueden tambien ser utiles en el tratamiento de adultos que necesitan del tratamiento, por ejemplo, para insuficiencia de vitamina D y para hiperparatiroidismo secundario en CKD y otras enfermedades y afecciones relacionadas con vitamina D.
PE2021000260A 2018-08-31 2019-08-30 Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso PE20211489A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725940P 2018-08-31 2018-08-31
PCT/IB2019/057360 WO2020044314A1 (en) 2018-08-31 2019-08-30 Vitamin d pediatric dosage forms, methods of making and using

Publications (1)

Publication Number Publication Date
PE20211489A1 true PE20211489A1 (es) 2021-08-11

Family

ID=68165642

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000260A PE20211489A1 (es) 2018-08-31 2019-08-30 Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso

Country Status (22)

Country Link
US (4) US11000480B2 (es)
EP (1) EP3843706A1 (es)
JP (2) JP7603000B2 (es)
KR (1) KR20210054539A (es)
CN (2) CN112912067B (es)
AU (4) AU2019329905B2 (es)
BR (1) BR112021003788A2 (es)
CA (1) CA3110020A1 (es)
CL (2) CL2021000493A1 (es)
CO (1) CO2021003805A2 (es)
CR (2) CR20210158A (es)
DE (1) DE202019005769U1 (es)
EA (1) EA202190633A1 (es)
EC (1) ECSP21021189A (es)
IL (2) IL322133A (es)
MX (1) MX2020011740A (es)
MY (1) MY210476A (es)
PE (1) PE20211489A1 (es)
PH (1) PH12021550413A1 (es)
SG (1) SG11202101905YA (es)
TW (1) TWI856972B (es)
WO (1) WO2020044314A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912067B (zh) 2018-08-31 2025-04-04 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法
TW202203936A (zh) 2020-04-06 2022-02-01 愛爾蘭商艾爾根製藥有限公司 啟動內源性抗菌藥物治療ｓａｒｓ－ｃｏｖ－２感染
CN120694962A (zh) 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
WO2022103635A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114176164A (zh) * 2021-12-17 2022-03-15 广东驱动力生物科技股份有限公司 反刍动物用水溶性抗应激助剂
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
ATE144424T1 (de) * 1991-04-09 1996-11-15 Takeda Chemical Industries Ltd Stabilisiertes vitamin d arzneimittel
ATE211387T1 (de) * 1992-06-22 2002-01-15 Bone Care Int Inc Oral 1alpha-hydroxyprevitamin d
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US8980334B2 (en) * 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
CA2882048C (en) * 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
JP5452236B2 (ja) * 2007-03-02 2014-03-26 ファーナム・カンパニーズ・インコーポレーテッド ロウ様物質を用いた徐放性組成物
KR101759244B1 (ko) 2007-04-25 2017-07-18 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
JP5518302B2 (ja) 2008-05-16 2014-06-11 一丸ファルコス株式会社 ポリマーミセルからの疎水性物質の徐放方法
CN101584683A (zh) * 2009-06-12 2009-11-25 沈阳药科大学 美托拉宗缓释胶囊及其制备方法
ES2898348T3 (es) * 2009-10-26 2022-03-07 Merck Sharp & Dohme Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
JP5546948B2 (ja) 2010-05-14 2014-07-09 理研ビタミン株式会社 多芯型マイクロカプセル
WO2012047098A1 (en) * 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
US9907758B2 (en) * 2012-01-09 2018-03-06 Panjab University Department Of Biotechnology (Dbt) Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
EP2822542A1 (en) * 2012-03-07 2015-01-14 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20160008377A1 (en) * 2014-07-12 2016-01-14 Aphios Corporation Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases
KR20170047265A (ko) 2014-08-07 2017-05-04 옵코 아일랜드 글로벌 홀딩스 리미티드 25-하이드록시비타민 d를 이용한 보조요법
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
KR20180059542A (ko) * 2015-10-07 2018-06-04 디에스엠 아이피 어셋츠 비.브이. 멀티비타민 압출물
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
CN108420797B (zh) 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法
CN112912067B (zh) 2018-08-31 2025-04-04 欧普科爱尔兰环球控股有限公司 儿童剂型、制造和使用方法

Also Published As

Publication number Publication date
CA3110020A1 (en) 2020-03-05
ECSP21021189A (es) 2021-04-29
KR20210054539A (ko) 2021-05-13
US20200338006A1 (en) 2020-10-29
WO2020044314A1 (en) 2020-03-05
JP2021535155A (ja) 2021-12-16
CL2023002539A1 (es) 2024-02-23
AU2019329905A1 (en) 2021-03-18
IL280937B1 (en) 2025-08-01
US20210401752A1 (en) 2021-12-30
AU2019329905B2 (en) 2024-02-01
MX2020011740A (es) 2021-04-19
EA202190633A1 (ru) 2021-07-12
TWI856972B (zh) 2024-10-01
DE202019005769U1 (de) 2022-01-13
JP2025060651A (ja) 2025-04-10
MY210476A (en) 2025-09-24
CN112912067A (zh) 2021-06-04
SG11202101905YA (en) 2021-03-30
US12433842B2 (en) 2025-10-07
IL322133A (en) 2025-09-01
US11000480B2 (en) 2021-05-11
AU2024202877A1 (en) 2024-05-23
IL280937B2 (en) 2025-12-01
CN112912067B (zh) 2025-04-04
US20220000783A1 (en) 2022-01-06
AU2021107174A4 (en) 2021-12-09
TW202034905A (zh) 2020-10-01
US12133917B2 (en) 2024-11-05
CL2021000493A1 (es) 2021-07-23
CO2021003805A2 (es) 2021-04-19
JP7603000B2 (ja) 2024-12-19
CR20210158A (es) 2021-05-21
EP3843706A1 (en) 2021-07-07
US20250025423A1 (en) 2025-01-23
PH12021550413A1 (en) 2021-09-27
CN120154576A (zh) 2025-06-17
CR20250081A (es) 2025-05-05
IL280937A (en) 2021-04-29
AU2021107168A4 (en) 2021-12-09
BR112021003788A2 (pt) 2021-06-08

Similar Documents

Publication Publication Date Title
PE20211489A1 (es) Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CO2018011063A2 (es) Métodos de tratamiento con vitamina d
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2017001913A1 (es) Composición tópica curativa
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
CL2017001680A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
CO2025003585A2 (es) Formulación líquida de belumosudil
CL2019001462A1 (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla.
CL2018002337A1 (es) Composición farmacéutica para prevenir y tratar trastornos del sueño
MX2018013567A (es) L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.